

7 May 2024

## Osteopore successfully raises A\$2.9m from Entitlement Offer

Singapore-founded regenerative medicine company **Osteopore Limited (ASX:OSX or the Company)** – a global leader in 3D-printed biomimetic and bioresorbable implants is pleased to announce the successful completion of its Renounceable Pro-Rata Entitlement Offer and Shortfall Offer to raise ~A\$3,000,000 (before costs) (**Entitlement Offer**) which closed on 2 April 2024.

The Entitlement Offer provided eligible shareholders with the opportunity to subscribe for ten (10) fully paid ordinary shares (**New Shares**) for every one (1) fully paid ordinary share held (**Shares**) on the (**Record Date**) – at an issue price of A\$0.029 per New Share – with one (1) free-attaching new option for every five (5) New Shares subscribed for, exercisable at A\$0.0387 each and expiring 2 April 2026. (**New Options**).

Under the Entitlement Offer, eligible shareholders were allowed to subscribe for additional shares (**Shortfall Offer**). Applications for the Shortfall Offer closed on 2 April 2024.

Further to withdrawal rights expiring on 6 May 2024, the Company was delighted to raise approximately A\$2,860,160 (before costs), representing a 95% take up rate by the eligible shareholders. Under the Entitlement Offer, eligible shareholders subscribed for 49,581,234 New Shares and 9,916,250 free-attaching New Options. Under the Shortfall Offer, eligible shareholders subscribed for 49,044,910 New Shares and 9,809,023 free-attaching New Options.

The issuance of New Shares and New Options under the Entitlement Offer and the Shortfall Offer will occur on 8 May 2024, with normal trading of the New Shares expected to commence on 9 May 2024. The New Shares will rank equally with existing ordinary shares on issue.

The Company entered into a mandate with Advance Capital Partners Pte Ltd (**Advance Capital**) in connection with fund raising and general corporate advisory activities (the



**Mandate**). In connection with the Mandate, Advance Capital will be entitled to a fee of 3% of the subscription amount from the Entitlement Offer.

Funds raised via the Entitlement Offer will strengthen Osteopore's balance sheet and maintain sales momentum while supporting the Company to develop breakthrough products, secure market approvals, acquire complementary technologies, explore mergers and acquisition (M&A) opportunities and increase working capital.

Osteopore continues to work towards developing the optimal conditions for revenue growth, whilst exploring different ways to improve the performance of our cost centres and streamline our expenses, with the effects of this starting to kick in over Q1 CY 2024.

In Q1 CY24, the Company achieved its 5<sup>th</sup> straight quarter of uninterrupted revenue growth, which saw revenues peak at 76% Year-on-Year (YoY) and 15% Quarter-on-Quarter (QoQ).<sup>1</sup>

The Company wishes to thank its shareholders who participated in the Entitlement Offer for their ongoing commitment and dedication to Osteopore.

## ENDS

*This announcement dated 7 May 2024 has been authorised for release to the ASX by the Board of Osteopore Limited.*

For more information, please contact:

**Dr. Yujing Lim**

CEO & CTO

Osteopore Limited

E: [lim\\_yujing@osteopore.com](mailto:lim_yujing@osteopore.com)

**Isaac Stewart**

Media & Investor Relations

Purple

E: [istewart@purple.au](mailto:istewart@purple.au)

### About Osteopore Limited

Osteopore Limited is a Singapore-founded regenerative medicine company and a global leader in 3D-printed biomimetic and bioresorbable implants. The Company seeks to commercialise products that stimulate natural bone healing across multiple segments.

Osteopore creates patented scaffolds using 3D-printed biomimetic and bioresorbable materials to guide and nurture bone-forming cells.

---

<sup>1</sup> **ASX announcement:** 'Q1 CY24 Quarterly Report', 30 April 2024



Through our proprietary manufacturing process – which uses a naturally dissolving polymer – our patented scaffolds enable bone tissue growth, significantly reducing the post-surgery complications commonly associated with permanent bone implants.

#### Forward-Looking Statements

Some of the statements appearing in this announcement may be in the nature of forward-looking statements. You should be aware that such statements are only predictions and are subject to inherent risks and uncertainties. Those risks and uncertainties include factors and risks specific to the industries in which the Company operates and proposes to operate as well as general economic conditions, prevailing exchange rates and interest rates and conditions in the financial markets, among other things. Actual events or results may differ materially from the events or results expressed or implied in any forward-looking statement. No forward-looking statement is a guarantee or representation as to future performance or any other future matters, which will be influenced by a number of factors and subject to various uncertainties and contingencies, many of which will be outside the Company's control.

The Company does not undertake any obligation to update publicly or release any revisions to these forward-looking statements to reflect events or circumstances after today's date or to reflect the occurrence of unanticipated events. No representation or warranty, express or implied, is made as to the fairness, accuracy, completeness or correctness of the information, opinions or conclusions contained in this announcement. To the maximum extent permitted by law, neither of the Company's Directors, employees, advisors or agents, nor any other person, accepts any liability for any loss arising from the use of the information contained in this announcement. You are cautioned not to place undue reliance on any forward-looking statement. The forward-looking statements in this announcement reflect views held only as at the date of this announcement.

This announcement is not an offer, invitation or recommendation to subscribe for or purchase securities by the Company. Nor does this announcement constitute investment or financial product advice (nor tax, accounting or legal advice) and is not intended to be used for the basis of making an investment decision. Investors should obtain their own advice before making any investment decision.



For personal use only